stockrow
Friday 6 November 2026
Export GUTS’s income statement to Excel — free account
Fractyl Health, Inc.
GUTS Healthcare Biotechnology
Fractyl Health, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $93,000.00, down 22.5% from fiscal 2023.
- Revenue
- −57.1%
- EPS
- +71.9%
- Free cash flow
- +25.3%
- Total debt
- +1.54%
Quarter to June 2026, against a year earlier
0.94
0.04
+4.44%
Follow GUTS
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
3.00 | 4.10 | 4.45 | 4.16 | |
Current Ratio |
3.15 | 4.28 | 4.78 | 4.27 | |
Net Debt/EBITDA |
0.89 | 1.61 | 2.21 | 2.09 | |
Debt/Assets |
37.14% | 30.32% | 25.19% | 26.93% | |
Debt/Equity |
(18.29) | 1.41 | 3.23 | (9.68) | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.62 | (2.44) | 0.49 | 0.50 | |
Capex/Depreciation |
0.00 | 0.00 | (0.01) | (0.03) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.20) | (1.70) | (3.38) | (4.22) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.20) | (1.70) | (3.38) | (4.22) | |
Cash per Share |
3.57 | 4.78 | 12.91 | 14.42 | |
Shareholders Equity per Share |
(0.13) | 1.62 | 1.50 | (0.59) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.13) | 1.62 | 1.50 | (0.59) | |
Free Cash Flow |
(15.90) | (22.48) | (21.34) | (22.72) | |
Working Capital |
33.87 | 50.51 | 69.25 | 61.02 | |
Capital Expenditures |
— | — | 0.00 | (0.01) | |
Net Current Asset Value |
(34.04) | (12.09) | (24.37) | (37.75) | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
2.46 | 1.56 | 2.41 | 1.51 | |
Average Assets |
71.99 | 91.21 | 114.74 | 120.60 | |
Average Common Equity |
(9.94) | 13.88 | 18.94 | 23.57 |
Columns are period end dates · fundamentals updated 2 Nov 2026